Business
FEATURED STORIES
LB Pharma needed $350 million to advance a promising schizophrenia candidate at a time when the biotech markets were locked up tight. Fortunately, it wasn’t CEO Heather Turner’s first rodeo.
Rare disease drug developers struggle to survive in a biopharma investment market that prioritizes large patient populations. Initiatives like the Orphan Therapeutics Accelerator are attempting to solve what CEO Craig Martin says is not a science problem, but a math problem.
Eli Lilly’s win in a head-to-head trial drove Novo Nordisk’s market cap to pre-Wegovy levels not long after the victor became the first pharma company to top a $1 trillion valuation. It seems one company can do no right, while the other can do no wrong.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Agreement strengthens collaboration between the companies following submission of the first dossier to the European Medicines Agency (EMA) for a CrisBio® produced recombinant vaccine
Columbia, SC – Obsidio, Inc., a pre-clinical stage medical materials developer pioneering a universal embolic hydrogel designed to be delivered minimally invasively through a clinical catheter for blood vessel occlusion, announced the formation of its clinical advisory board.
Utilizing AI technology to streamline information analysis and contribute to progress in an emergent, yet vital frontier of medical science
Vivoryon Therapeutics AG, announced its third quarter business update for the period ending September 30, 2019.
Here are five high-quality examples of major bio organizations’ efforts to showcase their commitment to providing a positive D&I work environment.
Under the terms of the deal with BBA, BBA acquired a capped 4.5% royalty on net sales of KSI-301 that will be paid upon marketing approval.
IFM Therapeutics is launching its third subsidiary this year with a focus on developing next-generation small molecule immunotherapies for inflammatory diseases and cancers.
SkinBioTherapeutics has announced its full year results and released details of its strengthened board and management team following the appointment of Stuart Ashman CEO.
Panthera Biopartners has strengthened its management team with the appointment of Jane Restorick as Chief Commercial Officer.
Pharma and life science companies strengthen their leadership teams and boards of directors with this week’s appointments.